Search bioRxiv⌕ Search

bioRxiv · 10.1101/2023.04.10.536248

Diethylcarbamazine elicits Ca2+ signals through TRP-2 channels that are potentiated by emodepside in Brugia malayi muscles

Abstract

Filarial nematode infections are a major health concern in several countries. Lymphatic filariasis is caused by Wucheria bancrofti and Brugia spp. affecting over 120 million people. Heavy infections can lead to elephantiasis having serious effects on individuals lives. Although current anthelmintics are effective at killing the microfilariae in the bloodstream, they have little to no effect against adult parasites found in the lymphatic system. The anthelmintic diethylcarbamazine is one of the central pillars of lymphatic filariasis control. Recent studies have reported that diethylcarbamazine can open Transient Receptor Potential (TRP) channels on the muscles of adult female Brugia malayi leading to contraction and paralysis. Diethylcarbamazine has synergistic effects in combination with emodepside on Brugia inhibiting motility: emodepside is an anthelmintic that has effects on filarial nematodes and is under trials for treatment of river blindness. Here we have studied the effects of diethylcarbamazine on single Brugia muscle cells by measuring the change in Ca2+ fluorescence in the muscle using Ca2+-imaging techniques. Diethylcarbamazine interacts with the TRPC orthologue receptor TRP-2 to promote Ca2+ entry into the Brugia muscle cells which can activate SLO-1 Ca2+ activated K+ channels, the putative target of emodepside. A combination of diethylcarbamazine and emodepside leads to a bigger Ca2+ signal than when either compound is applied alone. Our study shows that diethylcarbamazine targets TRP channels to promote Ca2+ entry that is increased by emodepside activation of SLO-1 channels.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Williams, P. D., Kashyap, S. S., Robertson, A., Martin, R. J.. 2023-04-11. Diethylcarbamazine elicits Ca2+ signals through TRP-2 channels that are potentiated by emodepside in Brugia malayi muscles. https://doi.org/10.1101/2023.04.10.536248

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology↗

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology↗

Therapeutic effects of a purified chitin-binding protein from Moringa oleifera seeds on irinotecan-induced intestinal mucositis in mice

Intestinal mucositis is a common side effect of irinotecan-based anticancer regimens, affecting approximately 85% of colorectal cancer (CRC) patients undergoing chemotherapy. Current treatment options are mainly palliative. Moringa oleifera Lamarck, native to Northeast India, is known for its nutritional and therapeutic properties. Our research group has demonstrated that MoCBP4 (11.78 kDa), a thermostable chitin-binding protein isolated from Moringa oleifera seeds, possesses potent antinociceptive, antifungal, wound-healing, and anti-inflammatory activity, both orally and intraperitoneally. Therefore, this study aimed to evaluate the protective effect of Mo-CBP4 in a model of irinotecan (CPT-11)-induced intestinal mucositis. This study was approved by the Animal Research Ethics Committee of UFC - CEPA (9892300120) and (7796300120). Male Swiss mice (25-30 g) were divided into 3 groups: Group 1 received saline solution (0.9%, i.p.) once a day for seven days; Group 2 received irinotecan (75 mg/kg, i.p.) once a day for four days; Group 3 was treated for 7 days with Mo-CBP4 at a dose of 10 mg/kg e.v., respectively, 30 minutes before CPT-11, which was administered for 4 days. During the seven days, weight loss, diarrhea scores, and survival were evaluated. On the seventh day, blood was collected for leukocyte count, followed by euthanasia for duodenum collection and evaluation of the following parameters: small intestine length, intestinal contractility, histopathological and morphometric alterations, MPO, GSH, MDA, NO, cytokines (IL-1{beta}, IL-6, KC, TGF-{beta}, and IL-10), and PCR (IL-33, IL-17, Claudin-2, Occludin, and ZO-1). We evaluated the cytotoxicity of MoCBP4 in normal and tumor cells for 24h and 72h using the Sulforhodamine B (SRB) assay and its interference with the effect of SN38 [2.5M] (active metabolite of CPT-11) for 48h in murine colon cancer (MC38). We injected MC38 cells into male C57BL/6 mice (n=10; 25{+/-}2g) to induce a tumor amenable to treatment with CPT-11. We analyzed daily weight and palpable tumor growth with a digital caliper, and after sacrifice, we measured final tumor growth and MPO. Irinotecan (CPT-11) induced intestinal mucositis in mice, characterized by weight loss, diarrhea, increased mortality, leukopenia, decreased intestinal length, increased intestinal contractility, histopathological alterations (villous blunting, loss of crypt architecture, vacuolation, inflammatory cell infiltrate), and increased levels of MPO, IL-1{beta}, IL-6, KC, TGF-{beta}, IL-33, and Claudin 2. Increased MDA and decreased GSH levels were also observed. Treatment with Mo-CBP4 (10 mg/kg) significantly attenuated CPT-11-induced intestinal mucositis, improving diarrhea, increasing survival, reducing intestinal damage, and attenuating histopathological alterations. MoCBP4 was also able to decrease levels of MPO (35%), NO (48%), IL-1{beta} (52%), IL-6 (98%), KC (88%), TGF-{beta} (62%), IL-33, decrease MDA levels, and increase GSH. MoCBP4 did not exhibit cytotoxic activity in MC38, L929, SK-MEL, and B16F10 cell lines, and did not interfere with the cytotoxic effect of SN38. It also did not interfere with the antitumor effect of CPT-11 in a tumor transplant model. Therefore, Mo-CBP4 demonstrates important antidiarrheal, anti-inflammatory, and antioxidant activities that make it a promising therapeutic option for preventing and attenuating the severity of intestinal mucositis during CPT-11 chemotherapy treatment without interfering with the antitumor effect of irinotecan.

pharmacology and toxicology↗